Abstract: This invention relates to specific compounds and their pharmaceutically acceptable salts of the general formula: wherein Q is —CR?CR?— and Ring A is an aryl, heteroaryl or heterocyclic ring or ring system. This invention also relates to pharmaceutical compositions comprising such specific compounds or their pharmaceutically acceptable salts and a pharmaceutically acceptable carrier or adjuvant.
Type:
Grant
Filed:
December 5, 2011
Date of Patent:
November 19, 2013
Assignee:
ARIAD Pharmaceuticals, Inc.
Inventors:
Yihan Wang, Wei-Sheng Huang, Rajeswari Sundaramoorthi, Xiaotian Zhu, R. Mathew Thomas, William C. Shakespeare, David C. Dalgarno, Tomi K. Sawyer
Abstract: The present invention relates to compounds of formula (I): wherein; R1 represents hydrogen or C1-3alkyl; n is an integer having a value of 1 to 5; X represents O or NH; Y represents C or N; or a pharmaceutically acceptable salt thereof, have been shown to be inducers of human interferon and may possess an improved profile with respect to known inducers of human interferon, for example enhanced potency. The compounds of the invention may therefore be useful in the treatment of various disorders, in particular the treatment of infectious diseases, cancer, allergic diseases and other inflammatory conditions, and their use as vaccine adjuvants.
Type:
Grant
Filed:
February 8, 2011
Date of Patent:
November 5, 2013
Assignee:
GlaxoSmithKline LLC
Inventors:
Helene Bazin-Lee, Diane Mary Coe, David A. Johnson, Charlotte Jane Mitchell
Abstract: Inhibitors of the enzyme beta-lactamase are provided comprising compounds of formula (II) wherein R1 or R2 is a pyridyl group and R5 is a group of formula The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided.
Type:
Grant
Filed:
September 27, 2012
Date of Patent:
November 5, 2013
Assignee:
Southern Methodist University
Inventors:
John D. Buynak, Anjaneyulu Sheri, Sundar Ram Reddy Pagadala
Abstract: The invention relates to a range of original xanthine derivatives substituted in 1 -and 7-positions with benzhydryl-4-piperazinyl-1-alkane fragments. A method for obtaining 3-methyl-7-[4-(benzhydryl-4-piperazinyl-1)butyl]xanthine and the salts thereof with organic and inorganic acids by alkylating the 7-potassium salt of 3-methylxanthine by 1,4-dibromobutane, by subsequently interacting the thus formed 7-(4-bromobutyl)-3-methylxanthine with 1-benzhydrylpiperazinyl and by neutralising the thus obtained radical 7-/4-(4-benzhydrylpiperazinyl-1) butyl/-3-methylxanthine by an organic or inorganic acid is also disclosed.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
October 29, 2013
Assignee:
A.B. Intelpharm Limited
Inventors:
Robert G. Glushkov, Sergei D. Juzhakov, Olga S. Fominova, Nelli M. Sazonova, Elena M. Dolginova, Vadim A. Shorr, Mikhail V. Borovkov, Valentina V. Asnina
Abstract: The present invention relates to compounds of formula (I): wherein R1 is C1-6alkylamino, or C1-6alkoxy; R2 is a group having the structure: n is an integer having a value of 1 to 6; Het is a 6-membered saturated heterocycle containing one nitrogen atom wherein Het is attached to the —(CH2)n— moiety at any carbon atom of the heterocycle; R3 is hydrogen, C1-8alkyl, or C3-7cycloalkylC0-6alkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.
Type:
Grant
Filed:
August 7, 2009
Date of Patent:
October 22, 2013
Assignee:
GlaxoSmithKline LLC
Inventors:
Helene Bazin-Lee, Diane Mary Coe, Linos Lazarides, Charlotte Jane Mitchell, Stephen Allan Smith, Naimisha Trivedi
Abstract: A novel substance exhibiting physiologically active effects is produced from a tea leaf. A novel polyphenol derivative is produced, for example, by subjecting a microbially fermented tea leaf obtained by culturing Aspergillus sp. (PK-1) with a tea leaf, to an extraction treatment.
Type:
Grant
Filed:
September 17, 2010
Date of Patent:
October 15, 2013
Assignees:
Kabaushiki Kaisha Riverson, Saga University
Abstract: Novel heterocyclic derivatives based on N6-substituted adenine, having anticancer, mitotic, immunosuppressive and antisenescent properties for plant, animal and human cells and methods of their preparation. Included are also pharmaceutical compositions, cosmetic preparations and growth regulators, which contain these derivatives as active compound and the use of these derivatives for the preparation of drugs, cosmetic preparations, in biotechnological processes, in cosmetics and in agriculture.
Type:
Grant
Filed:
July 18, 2007
Date of Patent:
October 8, 2013
Assignee:
USTAV Experimentalni Botaniky Akademie Ved Ceske Republiky
Inventors:
Igor Popa, Jan Holub, René Lenobel, Stefaan Werbrouck, Karel Dolezal, Miroslav Strnad, Marek Zatloukal, Frank J. Massino
Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.